60
patented urinary biomarkers for the diagnosis of prostate cancer
50%
reduction of prostate biopsies performed on men who have no prostate cancer
1.5 M
CHF in competitive grants raised for the academic R&D of PROBAN
40 M
men could benefit from PROBAN every year
HIGHLY-SENSITIVE, NON-INVASIVE DIAGNOSTICS
INNOVATIVE
IMMUNOASSAYS
ONtrack Biomedical's core technology is an innovative and efficient method to develop highly-sensitive and highly-specific immunoassays quickly and cost-effectively
HIGH SENSITIVITY FOR PROSTATE CANCER
PROBAN has a negligible number of false negatives, meaning that only patients without prostate cancer result negative to our urine test
QUALITY OF LIFE
Thanks to a simple urine test, we will reduce to a half the number of men who will perform a prostate biopsy if they do not have a prostate tumor
NOVEL BIOMARKERS
ONtrack Biomedical AG has developed an innovative strategy to identify and validate novel and non-invasive biomarkers, applicable to any disease
GET IN TOUCH
ONTRACK Biomedical AG
c/o USZ (Universitätsspital Zurich)
Klinik für Urologie (4th Floor)
Wagistrasse 21
8952 Schlieren